Population ageing and cardiovascular health: the case of Greece

First wave of SARS-COV2 in Europe: Study and typology of the 15 worst affected European countries

Since 11 March 2020 when officially declared a global pandemic, Covid-19 (or SARS-COV2) has turned out to be a multifaceted disease differently affecting countries and individuals. What makes certain countries more vulnerable than others has attracted the interest of scientists from various disciplines. This paper intends to compare the impact of demographic parameters, population health conditions and policy actions on prevalence and fatality levels of Covid-19 during the first 3 months since its declaration of global pandemic. A country-level exploratory analysis has been conducted in order to assess how demography, national health conditions and measures taken interact and condition the disease outcomes. Analysis relies on publicly available data on Covid-19 reported cases, deaths and number of persons tested. Those data are combined with demographic parameters (sex ratio, mean age, population density and life expectancy), health data (cardiovascular death rate, diabetes prevalence, share of smokers among males and females and number of hospital beds) and information about relative national policies aiming the management of the pandemic (lockdown timing and duration). Our analysis confirms the diversity of factors and the complexity of their interaction in explaining the propagation and fatality of the disease across Europe. Our findings question some well-established attitudes concerning the role of demographic variables and public health conditions in the spread of the disease.

Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement

Since the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has emerged from China, the infection (novel corona virus disease-2019, COVID-19) has affected many countries and led to many deaths worldwide. Like SARS-CoV, angiotencin converting enzyme (ACE)2 as a functional receptor for SARS-CoV2 is essential for the virus to make an entry into the cell. ACE2 is a part of Renin-Angiotensin-Aldosterone System, which is expressed in several organs that opposes the angiotensin (Ang) II functions by converting Ang II to Ang (1-7), the one with vasodilation effects. The death rate of COVID-19 is estimated to be approximately 3.4%; however, some comorbid conditions like underlying cardiovascular disease, hypertension, and diabetes increase the risk of mortality. In addition, cardiovascular involvement as a complication of SARS-CoV2 could be direct through either ACE2 receptors that are expressed tremendously in the heart, or by the surge of different cytokines or by acute respiratory distress syndrome-induced hypoxia. Traditional risk factors could aggravate the process of COVID-19 infection that urges the triage of these high-risk patients for SARS-CoV2. Currently, there is no effective, proven treatment or vaccination for COVID-19, but many investigators are struggling to find a treatment strategy as soon as possible. Some potential medications like chloroquine by itself or in combination with azithromycin and some protease inhibitors used for the treatment of COVID-19 have cardiovascular adverse effects, which should be kept in mind while the patients taking these medications are being closely monitored.